Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation

Elena Gardella1,2, Felicitas Becker3, Rikke S Møller1,2

  • 1Danish Epilepsy Center-Filadelfia, Dianalund, Denmark.

Annals of Neurology
|December 18, 2015
PubMed

Insights

Genetic analysis identified a novel SCN8A mutation causing benign infantile seizures and paroxysmal dyskinesia. This expands the understanding of combined epileptic and dyskinetic syndromes.

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Benign familial infantile seizures (BFIS), paroxysmal kinesigenic dyskinesia (PKD), and infantile convulsions and paroxysmal choreoathetosis (ICCA) are related autosomal dominant disorders.
  • Mutations in the PRRT2 gene are found in most familial and sporadic cases of these conditions.

Observation:

  • Whole exome or targeted gene panel sequencing was performed on PRRT2-negative families with BFIS or ICCA.
  • A recurrent heterozygous missense mutation (c.4447G>A; p.E1483K) in the SCN8A gene was identified in three families.

Findings:

  • The SCN8A mutation cosegregated with the phenotype in 16 affected individuals across three families.
  • Affected individuals presented with infantile-onset seizures, and some later developed paroxysmal dyskinetic or shivering episodes.
  • Most patients had normal development and neuroimaging, with normal interictal EEG in most cases.

Implications:

  • SCN8A is established as a novel gene associated with BFIS/ICCA, broadening the genetic basis of these syndromes.
  • This finding expands the clinical-genetic spectrum of combined epileptic and dyskinetic disorders.
  • Understanding the role of SCN8A in these conditions may lead to improved diagnostics and targeted therapies.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
949
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.3K